



CONSENT RESOLUTIONS OF THE DIRECTORS OF MOSS GENOMICS INC. (the “Company”)

The following resolutions were consented to and adopted in writing by the undersigned, being all of the directors of the Company, effective as of May 29, 2026.

The undersigned, being all of the directors of **Moss Genomics Inc.** (the “**Company**”), hereby adopt the following resolutions pursuant to applicable corporate law and the Company’s constating documents:

Approval of Q3 Financial Statements and Management’s Discussion & Analysis

WHEREAS management has presented to the Board of Directors the Company’s unaudited condensed interim financial statements for the three and nine months ended March 31, 2026 (the “Financial Statements”), together with the related Management’s Discussion and Analysis (“MD&A”);

WHEREAS the Board has reviewed the Financial Statements and MD&A and has had the opportunity to discuss the contents thereof with management;

WHEREAS the Board has determined that the Financial Statements have been prepared in accordance with applicable accounting standards and that the MD&A fairly presents the financial condition, results of operations, and cash flows of the Company for the relevant period, in all material respects;

NOW THEREFORE BE IT RESOLVED THAT:

1. Approval of Financial Statements

The unaudited condensed interim financial statements of the Company for the three and nine months ended March 31, 2026, be and are hereby approved.

2. Approval of MD&A

The Management’s Discussion and Analysis relating to such interim financial statements be and is hereby approved.

3. Authorization for Filing

Any director or officer of the Company is hereby authorized and directed to:

- Finalize the Financial Statements and MD&A in substantially the form presented to the Board;
- Execute any required certificates;
- File the Financial Statements and MD&A on SEDAR+ and make such other regulatory filings as may be required;
- Take all other actions necessary or desirable to give effect to the foregoing resolutions.

4. Ratification

All actions previously taken by the directors or officers of the Company in connection with the preparation and review of the Financial Statements and MD&A are hereby ratified, confirmed, and approved.


CERTIFICATION

The undersigned hereby certifies that the foregoing resolutions were duly adopted by the Board of Directors of Moss Genomics Inc. on May 29, 2026, and remain in full force and effect as of the date hereof.

[Remainder of page intentionally left blank]

Execution in Counterpart

BE IT FURTHER RESOLVED that these resolutions may be signed in as many counterparts as may be necessary, including by facsimile or other electronic means, each of which so signed shall be deemed to be an original, and such counterparts together shall constitute one and the same instrument and, notwithstanding the date of execution, shall be deemed to bear the effective date set forth above.



CHENGQI LIU



SIGNED VIA ILOVEPDF
HUNTER JORDAN

BD961125-0B12-46F7-BFB6-D7FF9CEA5034



JOSEPH DE PINTO